Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its 139-year history.
The company expects to start around 10 new phase 2 and 3 trials within the next 12 to 18 months, supported by an R&D spend that reached €5.8 billion last year, a rise of 14% and accounting for 22.5% of net sales.